Analyst Price Targets — XENE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 23, 2026 9:10 pm | — | Wolfe Research | $60.00 | $42.72 | TheFly | Xenon Pharmaceuticals initiated with an Outperform at Wolfe Research |
| February 10, 2026 12:23 pm | — | Stifel Nicolaus | $66.00 | $42.43 | TheFly | Xenon Pharmaceuticals price target raised to $66 from $60 at Stifel |
| November 4, 2025 2:42 pm | — | RBC Capital | $58.00 | $39.63 | TheFly | Xenon Pharmaceuticals price target raised to $58 from $55 at RBC Capital |
| November 4, 2025 2:06 pm | Josh Schimmer | Cantor Fitzgerald | $55.00 | $39.78 | StreetInsider | Cantor Fitzgerald Reiterates Overweight Rating on Xenon Pharmaceuticals (XENE) |
| November 4, 2025 11:33 am | Benjamin Burnett | Wells Fargo | $44.00 | $41.12 | TheFly | Xenon Pharmaceuticals price target lowered to $44 from $48 at Wells Fargo |
| February 28, 2025 1:18 pm | — | Wedbush | $42.00 | $37.02 | TheFly | Xenon Pharmaceuticals price target lowered to $42 from $43 at Wedbush |
| October 10, 2024 8:31 am | Danielle Brill | Raymond James | $50.00 | $39.42 | TheFly | Xenon Pharmaceuticals resumed with an Outperform at Raymond James |
| October 1, 2024 6:06 am | Douglas Tsao | H.C. Wainwright | $53.00 | $39.37 | TheFly | Xenon Pharmaceuticals initiated with a Buy at H.C. Wainwright |
| August 9, 2024 9:57 am | Laura Chico | Wedbush | $49.00 | $41.05 | TheFly | Xenon Pharmaceuticals price target lowered to $49 from $50 at Wedbush |
| June 18, 2024 6:20 am | Brian Abrahams | RBC Capital | $55.00 | $36.25 | StreetInsider | RBC Capital Reiterates Outperform Rating on Xenon Pharmaceuticals (XENE) |
Latest News for XENE
Xenon Pharmaceuticals Inc. (NASDAQ: XENE - Get Free Report) was the target of some unusual options trading on Wednesday. Traders bought 6,053 call options on the company. This is an increase of approximately 407% compared to the average volume of 1,195 call options. Wall Street Analysts Forecast Growth Several brokerages recently issued reports on XENE. Stifel
Xenon Pharmaceuticals Inc. (NASDAQ: XENE - Get Free Report) hit a new 52-week high on Friday after Needham and Company LLC raised their price target on the stock from $55.00 to $58.00. Needham and Company LLC currently has a buy rating on the stock. Xenon Pharmaceuticals traded as high as $46.99 and last traded at $44.78,
XENE posts wider Q4 loss as R&D jumps 47%, but late-stage azetukalner studies and a $586M cash runway keep its pipeline in focus.
Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026 Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and neuropsychiatry indications with Phase 3 X-NOVA2 MDD topline data expected in H1 2027 Data from two Phase 1 studies of novel Na V 1.7 (XEN1701) and K V 7 (XEN1120) candidates expected in 2026 to support Phase 2 proof-of-concept studies in pain Pro…
Connecticut-based Braidwell sold 1,779,953 Xenon Pharmaceuticals shares in the fourth quarter; the estimated transaction value was $74.76 million based on quarterly average prices. Meanwhile, the quarter-end Xenon position value decreased by $62.94 million, reflecting both trading and stock price movement.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for XENE.
U.S. House Trading
No House trades found for XENE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.